Isis Pharmaceuticals Inc. ISIS:NASDAQ

Notable Quotes

"CYTR's preclinical data for aldoxorubicin has been very supportive, and its phase 1b/2 trial has shown quite promising, albeit early stage, efficacy." (6/13/13) CytRx Corp. - The Life Sciences Report Interview with Michael Aikenhead More�>

"ATHX is an exciting story and definitely a company to watch." (6/6/13) Athersys Inc. - The Life Sciences Report Interview with Christian Glennie More�>

"NEO has been able to continue to grow the topline nicely and maintain margins of more than 45%." (5/30/13) NeoGenomics Laboratories - The Life Science Report with Kevin DeGeeter More�>

"OPK's 4Kscore is approved in Europe and should be approved in the U.S. sometime in 2013." (5/30/13) OPKO Health Inc. - The Life Science Report with Kevin DeGeeter More�>

"CTH is very early in the game with a very good and relatively derisked idea." (5/30/13) Cynapsus Therapeutics Inc. - The Life Science Report with Ori Hershkovitz More�>

Companies

Last:
Change:		Change(%):
Volume:		Open:
High:		Low:
52Wk High:		52Wk High:

Isis Pharmaceuticals Inc.

TICKER: ISIS:NASDAQ

Would you like more information on this company?

First Name *

Last Name

Email *

Phone

* Required

In addition, I would like to receive The Life Sciences Report Newsletter

Fact sheets, annual reports, webinars, CEO interviews and more, may be available for this company. Fill out this form and your contact information will be shared with this company to provide you with additional information.